Efficacy and safety of calcitonin gene‐related peptide antagonists in migraine treatment: A meta‐analysis
Abstract Introduction We systematically reviewed the efficacy and safety of Calcitonin Gene‐Related Peptide (CGRP) antagonists for migraine treatment. Methods Various databases including PubMed, Embase, The Cochrane Library, Chinese National Knowledge Infrastructure (CNKI), WanFang Data were electro...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-04-01
|
| Series: | Brain and Behavior |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/brb3.2542 |
| _version_ | 1797737310144430080 |
|---|---|
| author | Tingting Huang Yang Xu Yajie Chen Jing Bian Zhaohu Chu Shoucai Zhao Lingsong Ma |
| author_facet | Tingting Huang Yang Xu Yajie Chen Jing Bian Zhaohu Chu Shoucai Zhao Lingsong Ma |
| author_sort | Tingting Huang |
| collection | DOAJ |
| description | Abstract Introduction We systematically reviewed the efficacy and safety of Calcitonin Gene‐Related Peptide (CGRP) antagonists for migraine treatment. Methods Various databases including PubMed, Embase, The Cochrane Library, Chinese National Knowledge Infrastructure (CNKI), WanFang Data were electronically searched for randomized controlled trials (RCTs) on CGRP antagonists for migraine treatment since inception to March 2021. The trials were screened for inclusion, after which the methodological quality of the included trials was assessed. Then meta‐analysis was performed using the Revman 5.3 software. Results A total of 26 RCTs involving 21,736 patients were included. The CGRP antagonists group included 13,635 patients while the control group included 8101 patients. Meta‐analysis showed that compared to the control group, CGRP antagonists were associated with various significant effects, including the following outcome indicators: (1) number of patients with ≥50% reduction from baseline in mean monthly migraine days (RR = 1.50, 95% CI [1.39,1.62], p < .00001); (2) number of patients with pain free at 2 h postdose (RR = 1.98, 95% CI [1.77, 2.20], p < .00001), and (3) number of patients with 2–24 h sustained pain free postdose (RR = 2.18, 95% CI [1.93, 2.46], p < .00001). However, the number of patients with any adverse events was significantly high in the antagonists group, relative to the control group (RR = 1.08, 95% CI [1.04, 1.12], p < .0001). Conclusions CGRP antagonists are significantly effective for migraine treatment; however, they are associated with various adverse events. Due to limitations with regards to quantity and quality of the included studies, the above conclusions should be verified by more high quality studies. |
| first_indexed | 2024-03-12T13:26:49Z |
| format | Article |
| id | doaj.art-c1913acdb20f4e4697cee456a6bf5b38 |
| institution | Directory Open Access Journal |
| issn | 2162-3279 |
| language | English |
| last_indexed | 2024-03-12T13:26:49Z |
| publishDate | 2022-04-01 |
| publisher | Wiley |
| record_format | Article |
| series | Brain and Behavior |
| spelling | doaj.art-c1913acdb20f4e4697cee456a6bf5b382023-08-25T04:42:42ZengWileyBrain and Behavior2162-32792022-04-01124n/an/a10.1002/brb3.2542Efficacy and safety of calcitonin gene‐related peptide antagonists in migraine treatment: A meta‐analysisTingting Huang0Yang Xu1Yajie Chen2Jing Bian3Zhaohu Chu4Shoucai Zhao5Lingsong Ma6Department of Neurology The First Affiliated Hospital of Wannan Medical Collage Wuhu Anhui ChinaDepartment of Neurology The First Affiliated Hospital of Wannan Medical Collage Wuhu Anhui ChinaDepartment of Neurology The First Affiliated Hospital of Wannan Medical Collage Wuhu Anhui ChinaDepartment of Neurology The First Affiliated Hospital of Wannan Medical Collage Wuhu Anhui ChinaDepartment of Neurology The First Affiliated Hospital of Wannan Medical Collage Wuhu Anhui ChinaDepartment of Neurology The First Affiliated Hospital of Wannan Medical Collage Wuhu Anhui ChinaDepartment of Neurology The First Affiliated Hospital of Wannan Medical Collage Wuhu Anhui ChinaAbstract Introduction We systematically reviewed the efficacy and safety of Calcitonin Gene‐Related Peptide (CGRP) antagonists for migraine treatment. Methods Various databases including PubMed, Embase, The Cochrane Library, Chinese National Knowledge Infrastructure (CNKI), WanFang Data were electronically searched for randomized controlled trials (RCTs) on CGRP antagonists for migraine treatment since inception to March 2021. The trials were screened for inclusion, after which the methodological quality of the included trials was assessed. Then meta‐analysis was performed using the Revman 5.3 software. Results A total of 26 RCTs involving 21,736 patients were included. The CGRP antagonists group included 13,635 patients while the control group included 8101 patients. Meta‐analysis showed that compared to the control group, CGRP antagonists were associated with various significant effects, including the following outcome indicators: (1) number of patients with ≥50% reduction from baseline in mean monthly migraine days (RR = 1.50, 95% CI [1.39,1.62], p < .00001); (2) number of patients with pain free at 2 h postdose (RR = 1.98, 95% CI [1.77, 2.20], p < .00001), and (3) number of patients with 2–24 h sustained pain free postdose (RR = 2.18, 95% CI [1.93, 2.46], p < .00001). However, the number of patients with any adverse events was significantly high in the antagonists group, relative to the control group (RR = 1.08, 95% CI [1.04, 1.12], p < .0001). Conclusions CGRP antagonists are significantly effective for migraine treatment; however, they are associated with various adverse events. Due to limitations with regards to quantity and quality of the included studies, the above conclusions should be verified by more high quality studies.https://doi.org/10.1002/brb3.2542CGRP antagonistsmigrainemeta‐analysisrandomized controlled trial |
| spellingShingle | Tingting Huang Yang Xu Yajie Chen Jing Bian Zhaohu Chu Shoucai Zhao Lingsong Ma Efficacy and safety of calcitonin gene‐related peptide antagonists in migraine treatment: A meta‐analysis Brain and Behavior CGRP antagonists migraine meta‐analysis randomized controlled trial |
| title | Efficacy and safety of calcitonin gene‐related peptide antagonists in migraine treatment: A meta‐analysis |
| title_full | Efficacy and safety of calcitonin gene‐related peptide antagonists in migraine treatment: A meta‐analysis |
| title_fullStr | Efficacy and safety of calcitonin gene‐related peptide antagonists in migraine treatment: A meta‐analysis |
| title_full_unstemmed | Efficacy and safety of calcitonin gene‐related peptide antagonists in migraine treatment: A meta‐analysis |
| title_short | Efficacy and safety of calcitonin gene‐related peptide antagonists in migraine treatment: A meta‐analysis |
| title_sort | efficacy and safety of calcitonin gene related peptide antagonists in migraine treatment a meta analysis |
| topic | CGRP antagonists migraine meta‐analysis randomized controlled trial |
| url | https://doi.org/10.1002/brb3.2542 |
| work_keys_str_mv | AT tingtinghuang efficacyandsafetyofcalcitoningenerelatedpeptideantagonistsinmigrainetreatmentametaanalysis AT yangxu efficacyandsafetyofcalcitoningenerelatedpeptideantagonistsinmigrainetreatmentametaanalysis AT yajiechen efficacyandsafetyofcalcitoningenerelatedpeptideantagonistsinmigrainetreatmentametaanalysis AT jingbian efficacyandsafetyofcalcitoningenerelatedpeptideantagonistsinmigrainetreatmentametaanalysis AT zhaohuchu efficacyandsafetyofcalcitoningenerelatedpeptideantagonistsinmigrainetreatmentametaanalysis AT shoucaizhao efficacyandsafetyofcalcitoningenerelatedpeptideantagonistsinmigrainetreatmentametaanalysis AT lingsongma efficacyandsafetyofcalcitoningenerelatedpeptideantagonistsinmigrainetreatmentametaanalysis |